Royal Jelly Research

Systematic review summarizing the composition, bioactive components, and health effects of royal jelly across preclinical and clinical research. The authors screened PubMed, Scopus, Web of Science, and Google Scholar for studies on royal jelly's therapeutic applications, synthesizing findings across metabolic, hormonal, cardiovascular, neurological, immunological, and dermatological domains.

The review highlights 10-hydroxy-2-decenoic acid (10-HDA) as the signature fatty acid of royal jelly along with major royal jelly proteins (MRJPs) as key drivers of biological activity. Evidence summarized includes improvements in glycemic control and lipid profile in diabetic populations, reductions in menopausal symptoms, modulation of testosterone and fertility markers, antioxidant and anti-inflammatory effects, and emerging neuroprotective and wound-healing data.

The authors conclude that royal jelly is a promising functional food and therapeutic intervention with mechanistic plausibility and consistent preclinical support, but emphasize that most human trials are small, short, and heterogeneous. They call for standardized formulations, larger dose-ranging RCTs, and better characterization of active constituents before strong clinical recommendations can be made.

Double-blind, randomized placebo-controlled clinical trial conducted in Bandar Abbas, Iran, enrolling 200 postmenopausal women aged 45-60. Participants received either 1000 mg/day of royal jelly capsules or placebo for 8 weeks. The primary outcome was menopausal symptom score measured by the Menopause Rating Scale.

Baseline scores did not differ between groups. After 8 weeks, mean menopausal symptom scores decreased significantly in the royal jelly group but not in the placebo group, with a statistically significant between-group difference favoring royal jelly. Improvements spanned somatic, psychological, and urogenital domains.

This is one of the larger RCTs of royal jelly for menopause. It strengthens the evidence base for a meaningful symptomatic effect of 1 g/day over two months and is a core reference in subsequent meta-analyses of royal jelly for postmenopausal symptoms.

Systematic review synthesizing evidence from randomized clinical trials and experimental studies on the effects of royal jelly on glycemic control, lipid profile, and oxidative stress in diabetes mellitus. The authors searched major databases through 2018 and included studies in both diabetic humans and animal models.

Across included trials, royal jelly supplementation was associated with substantial improvements in triglycerides, total cholesterol, HDL, LDL, VLDL, and Apo-A1, along with significant reductions in HbA1c and increases in insulin concentration. Fasting blood glucose was reduced in several human RCTs, most notably at doses of 1-3 g/day over 8 weeks.

The authors concluded that royal jelly may improve glycemic status, lipid profile, and oxidative stress markers in diabetes mellitus. However, they emphasized that the number and size of human RCTs remain limited, quality is mixed, and larger, longer trials are needed before royal jelly can be formally recommended as an adjunct for diabetes management.

Double-blind placebo-controlled RCT in 42 healthy Japanese postmenopausal women (mean age ~55) randomized to 800 mg/day of protease-digested lyophilized royal jelly powder or a dextrin placebo for 12 weeks. Menopausal symptoms were assessed every 4 weeks using a standardized questionnaire covering physical and psychological domains.

The enzyme-treated royal jelly group showed significantly greater improvement than placebo in backache/low back pain and anxiety scores after 12 weeks. No serious adverse events were reported, and compliance was high. The authors proposed that royal jelly's phytoestrogen-like activity and mild anti-inflammatory effects may underlie the symptomatic relief.

Though sample size was small, this trial is frequently cited as mechanistic evidence that royal jelly can meaningfully modulate menopausal symptoms at a modest dose. It supports a targeted role for royal jelly in postmenopausal women with musculoskeletal and mood-related complaints.

Randomized, parallel-group pilot RCT in 50 female volunteers with type 2 diabetes. Participants were allocated via random block procedure to either 1000 mg/day of royal jelly soft gels or placebo for 8 weeks. Glycemic indices, insulin concentration, and oxidative stress markers were measured before and after the intervention.

The royal jelly group showed significant reductions in mean HbA1c and significant increases in mean serum insulin compared with placebo. Changes in fasting blood glucose favored royal jelly but reached statistical significance only in some subgroup analyses. Antioxidant capacity increased and oxidative stress markers decreased in the royal jelly group.

Though modest in size, this trial is frequently cited as early human evidence that royal jelly can improve long-term glycemic control and insulin levels in type 2 diabetes. The authors recommended replication in larger, mixed-sex cohorts and with longer follow-up before clinical use.

Randomized, placebo-controlled, double-blind trial in 61 healthy Japanese volunteers aged 42-83. Participants were randomized to 3000 mg of royal jelly in 100 ml liquid daily or a matched placebo liquid for 6 months. The primary outcomes were anthropometric measurements and a broad panel of biochemical markers, including hematology, metabolic, hormonal, and mental health indices.

Fifty-six participants (30 royal jelly, 26 placebo) were analyzed. Compared with placebo, the royal jelly group showed significant increases in red blood cell count and reductions in erythrocyte sedimentation rate, improved glucose tolerance on OGTT, increased serum DHEA-S, and better mental-health sub-scale scores on a standardized questionnaire. No serious adverse events were reported, and there were no adverse changes in liver or kidney function.

This is one of the longest-duration human RCTs of royal jelly and provides supportive evidence that chronic supplementation at 3 g/day is well-tolerated and associated with multiple modest but consistent metabolic and hematologic improvements in middle-aged to older adults.